Domagrozumab

N/A

Report date: 2023/12/31 20:00:33

Base Information

Drug NameDomagrozumab
Drug Alias NamePF-6252616PF-06252616
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionGrowth/differentiation factor 8 inhibitors
TargetsGrowth/differentiation factor 8
Therapy Area/IndicationsLimb girdle muscular dystrophy 2AMuscular Dystrophy, Duchenne
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBulgariaCanadaUnited States +[8] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer Inc
Active IndicationsN/A
Inactive IndicationsLimb girdle muscular dystrophy 2AMuscular Dystrophy, Duchenne

Other Information

ATC CodeN/A
Related LinksN/A